The microbiome has emerged as one of the hottest new approaches for treating disease, and Second Genome Inc., a firm that describes itself as "the microbiome company" received significant interest at the recent BIO International Convention.
The company's senior vice president of corporate development, Mohan Iyer, took a few minutes at the San Diego meeting to speak with BioWorld News & Views on why the microbiome space is moving so rapidly. He also discussed Second Genome's specific work in the area and its success in landing big pharma partnerships with Janssen Biotech Inc. and Pfizer Inc.
News & Views is BioWorld's new series of video interviews with key biopharma executives, in which those experts and thought leaders share the latest clinical updates, provide insights into recent deals and financings and tackle a variety of questions.
Click here for BioWorld's interview with Second Genome's Iyer.